[A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens]

Reumatismo. Jan-Mar 2006;58(1):22-5. doi: 10.4081/reumatismo.2006.22.
[Article in Italian]

Abstract

Objective: To compare the SDAI values to DAS28 scores in RA patients undergoing different DMARD regimens.

Methods: The SDAI is an unweighted numerical sum of five outcome parameters: tender and swollen joint count (based on 28-joint assessment), patient and physician global assessment of disease activity (visual analogue scale: 0-10 cm) and level of C-reactive protein (mg/dl). 80 patients (F/M 68/12; age between 20-68 years, median 52) with active rheumatoid arthritis were prospectively enrolled in the study. The patients were randomly assigned to one of four groups according to the therapeutic regimens: group I: Methotrexate (MTX) 15 mg/weekly + salazopyrin 2 g/daily; group II: MTX 15 mg/weekly + infliximab 3 mg/Kg at time 0, 2, 4 and every 8 weeks; group III: MTX 15 mg/weekly + etanercept 25 mg/twice weekly; group IV: MTX 15 mg/weekly + adalimumab 40 mg/every other week. SDAI and DAS28 were determined at baseline and after 6 months in each patient. Mean changes in SDAI values were compared to those detected in DAS 28 at baseline and after 6 months.

Results: SDAI and DAS 28 were found to be significantly correlated at baseline. Moreover, changes in SDAI over time paralleled those in DAS, and were found to be significantly correlated.

Conclusions: SDAI is a valid measure of response to treatment in RA patients undergoing different therapeutic regimens.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Validation Study

MeSH terms

  • Adalimumab
  • Adult
  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • C-Reactive Protein / analysis
  • Drug Combinations
  • Etanercept
  • Female
  • Glucosamine / analogs & derivatives*
  • Glucosamine / therapeutic use
  • Humans
  • Immunoglobulin G / therapeutic use*
  • Infliximab
  • Male
  • Methotrexate / therapeutic use*
  • Middle Aged
  • Pain Measurement
  • Prospective Studies
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Severity of Illness Index*
  • Sulfasalazine / therapeutic use*
  • Treatment Outcome*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Drug Combinations
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Salazopyrine
  • Sulfasalazine
  • C-Reactive Protein
  • Infliximab
  • Adalimumab
  • Glucosamine
  • Etanercept
  • Methotrexate